Studies evaluating the safety and efficacy of ICIs included patients with multi-treated or metastatic GIST but did not specifically address the subgroup of SDH-deficient GIST due to the scarcity of this tumor subtype. The gene discussed is SDHB; the disease is gastrointestinal stromal tumor.